Document Detail


Evaluation of The Federal Bureau of Prisons protocol for selection of which hepatitis C-infected inmates are considered for treatment.
MedLine Citation:
PMID:  15844707     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The Federal Bureau of Prisons limits hepatitis C therapy to those inmates with certain biochemical abnormalities. To evaluate this protocol, an analysis was done on data collected on hepatitis C infected inmates in the Louisiana Department of Corrections. A quality assurance database of hepatitis C infected inmates evaluated in the Louisiana Department of Corrections was reviewed for liver biopsy and laboratory results. Patients were compared as to whether they would have been biopsied under the Federal Bureau of Prisons protocol and if there were histologic differences between those who would and those who would not have been biopsied. Of 490 inmates biopsied, 26% (129) had an alanine aminotransferase level between one and two times the upper limit of normal without other biochemical abnormalities. If treating stages 2-4, 48% of these would qualify for treatment (15% if treating stages 3-4). There was no statistical difference between this group and either the group with an alanine aminotransferase level between one and two times the upper limit of normal and with other laboratory abnormalities or the group with an alanine aminotransferase level greater than or equal to two times the upper limit of normal and without other abnormalities. In the Louisiana Department of Corrections, the Federal Bureau of Prisons protocol was neither sensitive nor specific enough at identifying those that should be considered for hepatitis C therapy.
Authors:
Monica M Pradhan; Ronald Horswell; Glenn Jones; Jennifer L Ramsey; William Cassidy
Related Documents :
24449707 - Luba-kasai men and the prevention of mother to child transmission (pmtct) of hiv progra...
9089027 - Anonymous hiv surveillance with risk-factor elicitation: at perth (for men) and cornton...
15812917 - India: court finds government has constitutional obligation to provide arvs to released...
23002987 - Developing a web site for human immunodeficiency virus prevention in a middle income co...
2034677 - Tumor necrosis factor alpha selectively sensitizes human immunodeficiency virus-infecte...
15250467 - Genetic variability analysis among clinical candida spp. isolates using random amplifie...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  50     ISSN:  0163-2116     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  2005 Apr 
Date Detail:
Created Date:  2005-04-22     Completed Date:  2005-05-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  714-8     Citation Subset:  AIM; IM    
Affiliation:
Louisiana State University Health Sciences Center, Department of Medicine, Baton Rouge, Louisiana 70805, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alanine Transaminase / blood
Antiviral Agents / therapeutic use*
Biopsy
Hepatitis C / blood,  drug therapy*,  pathology
Humans
Louisiana
Male
Patient Selection*
Prisons*
Sensitivity and Specificity
United States
Chemical
Reg. No./Substance:
0/Antiviral Agents; EC 2.6.1.2/Alanine Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential labeling by monoclonal antibodies Adnab-9 and anti-alpha-defensin 5 based on the distri...
Next Document:  Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or h...